Light inhibitors for asthma, lung and airway inflammation, respiratory, interstitial, pulmonary and fibrotic disease treatment

Abstract

Methods of treating inflammatory conditions, disease and disorders are provided. Method include, for example, contacting or administering a sufficient amount of a LIGHT inhibitor to a subject to treat the inflammatory condition, disease or disorder.

1 .- 5 . (canceled) 
     
     
         6 . A method for treating a fibrotic disease or disorder, comprising administering a sufficient amount of an inhibitor of LIGHT (p30 polypeptide) to a subject to treat the fibrotic disease or disorder, wherein the fibrotic disease or disorder is atopic dermatitis and the inhibitor of LIGHT (p30 polypeptide) comprises a) an LTβR (lymphotoxin beta receptor) polypeptide subsequence, b) a soluble LTβR, c) a dominant-negative variant of LTβR, or d) a chimeric polypeptide comprising an LTβR polypeptide, an LTβR polypeptide subsequence, a soluble LTβR or a dominant-negative variant. 
     
     
         7 - 12 . (canceled) 
     
     
         13 . The method of  claim 6 , wherein treatment reduces, decreases, inhibits, delays, eliminates or prevents the probability, severity, frequency, or duration of one or more symptoms associated with or caused by the fibrotic disease or disorder. 
     
     
         14 . The method of  claim 6 , wherein one or more symptoms of the fibrotic disease or disorder, is reduced, inhibited, abrogated, eliminated or reversed. 
     
     
         15 - 18 . (canceled) 
     
     
         19 . The method of  claim 6 , wherein the method reduces or inhibits progression, severity, frequency, duration or probability of a symptom of the fibrotic disease or disorder. 
     
     
         20 . The method of  claim 6 , wherein the fibrotic disease or disorder, is caused by an allergen or by exercise. 
     
     
         21 . The method of  claim 6 , wherein the fibrotic disease or disorder, is chronic or acute. 
     
     
         22 - 27 . (canceled 
     
     
         28 . The method of  claim 6 , wherein the inhibitor of LIGHT (p30 polypeptide) comprises an antibody or subsequence thereof that binds to LIGHT (p30 polypeptide), an antibody or subsequence thereof that binds to HVEM (herpesvirus entry mediator), or an antibody or subsequence thereof that binds to LTβR (lymphotoxin beta receptor). 
     
     
         29 . The method of  claim 28 , wherein the antibody is human or humanized. 
     
     
         30 - 33 . (canceled 
     
     
         34 . The method of  claim 6 , wherein the method reduces or decreases undesirable or abnormal eosinophil migration, chemotaxis or generation. 
     
     
         35 . The method of  claim 6 , further comprising contacting or administering a second drug to the subject prior to, with or following administering the inhibitor of LIGHT (p30 polypeptide). 
     
     
         36 . The method of  claim 35 , wherein the second drug comprises a hormone, steroid, anti-inflammatory or anti-allergy drug. 
     
     
         37 . (canceled) 
     
     
         38 . The method of  claim 35 , wherein the second drug comprises an anti-histamine, anti-leukotriene, anti-IgE, anti-α4 integrin, anti-β2 integrin, anti-CCR3 antagonist, β2 agonist or anti-selectin. 
     
     
         39 - 40 . (canceled) 
     
     
         41 . The method of  claim 6 , wherein the subject is administered the inhibitor of LIGHT (p30 polypeptide) one, two, three, four or more times daily, weekly, monthly, bi-monthly, or annually. 
     
     
         42 . The method of  claim 6 , wherein the amount of inhibitor of LIGHT (p30 polypeptide) administered is about 0.00001 mg/kg, to about 10,000 mg/kg, about 0.0001 mg/kg, to about 1000 mg/kg, about 0.001 mg/kg, to about 100 mg/kg, about 0.01 mg/kg, to about 10 mg/kg, about 0.1 mg/kg, to about 1 mg/kg body weight. 
     
     
         43 . The method of  claim 6 , wherein the amount of the inhibitor of LIGHT (p30 polypeptide) administered to the subject is less than about 0.00001 mg/kg body weight. 
     
     
         44 - 48 . (canceled)